Lead Investigator: João Sérgio Neves, Universidade do Porto
Title of Proposal Research: Effects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes
Vivli Data Request: 9964
Funding Source: None
Potential Conflicts of Interest: Dr. Neves has received consulting and speaking fees from Lilly. Any potential conflicts of interest will be appropriately disclosed when the research is presented and/or published.
Summary of the Proposed Research:
Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. Tirzepatide and semaglutide are both types of medication used to treat people who have type 2 diabetes. They work by mimicking hormones that are naturally secreted by the intestine after a meal, prompting secretion of the hormone insulin which helps control the blood sugar levels. Tirzepatide also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain that signal fullness.
Tirzepatide has been shown to improve some of the risks of cardiovascular complications (such as reducing the risk of heart attack and stroke) in people with diabetes. However, whether the benefits of tirzepatide are superior to those of semaglutide in the cardiovascular risk in patients with diabetes is still uncertain.
In this study we aim to evaluate the effects of tirzepatide, comparing with semaglutide, on markers of cardiovascular risk in people with type 2 diabetes such as weight loss, blood pressure and blood sugar and cholesterol levels. Any new information can then be used to inform patient care decisions.
Requested Studies:
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Data Contributor: Lilly
Study ID: NCT03987919
Sponsor ID: 17001